Product Information
Applications
Biological Information
Primary TargetATR
Primary Target IC<sub>50</sub>14 nM
Purity≥99% by HPLC
Physicochemical Information
Cell permeableY
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
Toxicity Standard Handling
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications

Documentation

ATR Inhibitor III, ETP-46464 - CAS 1345675-02-7 - Calbiochem SDS

Title

Safety Data Sheet (SDS) 

References

Reference overview
Thanasoula, M., et al. 2012. EMBO J. 31, 3398.
Toledo, L.I., et al. 2011. Nat Struct Mol Biol. 18, 721.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision09-December-2013 JSW
Synonyms2-methyl-2-(4-(2-oxo-9-(quinolin-3-yl)-2H-[1,3]oxazino[5,4-c]quinolin-1(4H)-yl)phenyl)propanenitrile, ATM and Rad3-Related Inhibitor III, Ataxia-Telangiectasia Mutated Inhibitor III, DNA-PK Inhibitor VI, ETP46464, ATM Inhibitor III, mTOR Inhibitor XIII, PI 3-K Inhibitor XIX
DescriptionA cell-permeable quinoline-containing heterotricyclic compound that acts as a potent inhibitor against mTOR, ATR, DNA-PK, PI 3-Kα, and ATM activity (IC50 = 0.6, 14, 36, 170, and 545 nM, respectively, in cell-free kinase assays) and preferentially suppresses ionization radiation/IR-induced cellular ATR activity (>90% inhibition of IR-induced Chk1 pSer345 at 500 nM) over ATM or DNA-PK activity (IC50 > 5 µM against IR-induced ATM pSer189, Chk2 pThr68, DNA-PKcs pSer2056, and γH2AX) in U2OS cells, while exhibiting much reduced or little potency toward a panel of 26 other kinases (>55% inhibition at 5 µM). Shown to synergize with UCN-01 (Cat. No. 539644) in replicative stress/RS induction in S-phase replicating U2OS (% population with pan-nuclear γH2AX staining = 6.0% and 0.2%, respectively, with or without 8 h 5 µM ETP-46464 treatment; 1.5-, 61-, and 190-fold of control RS, respectively, with 1 µM ETP-46464 alone, 50 nM UCN-01 alone, or combined treatment). Likewise, ETP-46464 is also demonstrated to further enhance oncogenic mutations-caused RS elevation in MEF cultures (% RS population without/with 5 µM ETP-46464 treatment = 0.3/0.6, 1.3/2.5, 0.9/3.0, 3.9/11.4, respectively, in wt, p53-/-, Cyclin E-transfected wt, and Cyclin E-transfected p53-/- MEF).
FormWhite powder
Intert gas (Yes/No) Packaged under inert gas
CAS number1345675-02-7
Chemical formulaC₃₀H₂₂N₄O₂
Structure formulaStructure formula
Purity≥99% by HPLC
SolubilityDMSO (10 mg/ml)
Storage +2°C to +8°C
Protect from light
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Standard Handling
ReferencesThanasoula, M., et al. 2012. EMBO J. 31, 3398.
Toledo, L.I., et al. 2011. Nat Struct Mol Biol. 18, 721.

Related Products & Applications

Categories

Life Science Research > Inhibitors and Biochemicals > Small Molecules & Inhibitors > DNA Damage/Repair > ATM Kinase Inhibitors